Full-Service Global Support for COVID-19 Studies

  • Post author:
  • Post category:

Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.

Continue ReadingFull-Service Global Support for COVID-19 Studies

Vaccine Development

  • Post author:
  • Post category:

Vaccines are critical to the eradication of infectious diseases worldwide. To achieve the FHI Clinical vision of a world where advances in vaccines help all people live longer, healthier lives, we’ve spent years honing our processes to respond to the urgency and complexity of vaccine trials, developing our global network of research-ready investigators and sites, and partnering with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, governments and non-governmental organizations.

Continue ReadingVaccine Development

Global Vaccine Development

  • Post author:
  • Post category:

To achieve our vision of a world where advances in vaccines help all people live longer, healthier lives, we’ve honed our processes to respond to the urgency and complexity of vaccine trials, developed our global network of investigators and sites, and partnered with organizations across public, private, academic and government sectors.

Continue ReadingGlobal Vaccine Development

Follow the Epi: Finding TB-Prevalent Populations to Guide TB Vaccine Protocol Design

In this plenary discussion, experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.

Continue ReadingFollow the Epi: Finding TB-Prevalent Populations to Guide TB Vaccine Protocol Design

About the PREVAIL Network

  • Post author:
  • Post category:

The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.

Continue ReadingAbout the PREVAIL Network

How Can We Streamline the Vaccine Development Process?

  • Post author:
  • Post category:

To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”

Continue ReadingHow Can We Streamline the Vaccine Development Process?